Summary of the Conference Call for Nanxiao Technology Industry Overview - The small nucleic acid delivery technology achieved a breakthrough in 2014, addressing degradation issues and expanding its application in common and chronic disease treatments, laying the foundation for market growth [2][3] - The small nucleic acid market is projected to reach $5.7 billion in 2024 and is expected to grow to $40-50 billion by 2030 [2][3] - The market for small nucleic acid solid-phase synthesis carriers is expected to reach $500 million by 2030 (approximately 3.5 billion RMB) [3] Company Insights - Nanxiao Technology holds a 70% market share in the peptide resin market and collaborates with major pharmaceutical companies like Novartis and GSK, anticipating at least a 50% share in the small nucleic acid solid-phase synthesis carrier market, equating to 1.7-1.8 billion RMB [2][3] - The company has a strong customer base, including top pharmaceutical firms such as Novartis, GSK, Annamics, Ionis, and BioGen, ensuring stable and high-quality order sources, which is a competitive advantage [4] - Nanxiao Technology, in collaboration with Japan's Nitto, possesses a comprehensive patent portfolio in small nucleic acids, enhancing its market competitiveness [2][4] Financial Performance and Growth Expectations - Since its IPO in 2015, Nanxiao Technology's revenue has grown from 300 million RMB to 2.6 billion RMB in 2024, with profits increasing from 50 million RMB to 800 million RMB [5] - The company has experienced two significant growth acceleration phases: commercialization of lithium extraction from salt lakes from 2017 to 2019, and the explosive growth of peptide solid-phase synthesis carriers from 2021 to 2023 [5] - It is expected that in 2026, the company will enter a third growth acceleration phase, with small nucleic acid business scaling from 0 to 1, and new products from key downstream customers like Novartis and GSK being launched [5] - Despite a slowdown in growth over the past two years leading to a decline in valuation, the anticipated industrialization and scaling of small nucleic acids is expected to drive both performance and valuation growth [5]

Core Viewpoint - Jiuzhou Pharmaceutical is entering a growth phase driven by its CDMO platform, which leverages its expertise in small molecules and TIDES, supported by a healthy project pipeline and high order visibility [3][5]. CDMO Business - The CDMO business is the main growth engine, with a robust project funnel and high order visibility. The company provides comprehensive lifecycle services from preclinical CMC to commercial production, deeply embedded in the supply chains of major pharmaceutical companies like Novartis and Roche [3]. - Key projects such as Noxafil and Ribociclib continue to generate revenue, while the rapid growth of the partnered product Vumerity is expected to provide sustained incremental growth [3]. - As of H1 2025, the company has a rich pipeline with 38 products on the market, 90 in Phase III, and 1,086 in Phase I/II, driving steady revenue growth [3]. API Business - The company focuses on specialty APIs, optimizing processes to enhance cost advantages. It holds a strong position in the CNS and anti-infection specialty API markets [4]. - Core product prices are expected to improve as industry inventory depletion nears completion, while new product categories are being introduced, including four specialty APIs by 2025 [4]. - Continuous process optimization and reduced development cycles are helping to maintain cost advantages, with an API business gross margin of 23.26% in H1 2025, up 2.08 percentage points year-on-year [4]. Formulations and CDMO - The company has made significant strides in its formulation and CDMO business through acquisitions and the establishment of its own facilities, completing its layout for generic and innovative drug formulations [4]. - As of Q3 2025, the formulation pipeline includes 22 projects, with 8 approved and 9 submitted for approval. The CDMO business has onboarded over 10 high-quality domestic and international clients, adding more than 30 new service projects [4]. - The formulation business is expected to maintain rapid growth in the future [4]. Investment Recommendation - The company has established a one-stop CDMO platform covering small molecules, peptides, conjugates, and formulations, serving major global pharmaceutical companies and achieving localized R&D in the US, Japan, and Germany [5]. - Projected net profits for 2025-2027 are estimated at 966 million, 1.128 billion, and 1.303 billion yuan, representing year-on-year growth of 59.4%, 16.8%, and 15.4% respectively [5]. - The current stock price corresponds to PE ratios of 16, 14, and 12 for 2025-2027. Given the company's growth prospects and strong order visibility, a target price of 26.64 yuan is set, with an initial "recommend" rating [5].

Market Performance - On Monday, major U.S. stock indices collectively declined, with the Dow Jones down 0.09% at 48,416.56 points, the Nasdaq down 0.59% at 23,057.41 points, and the S&P 500 down 0.16% at 6,816.51 points [1][2]. Tesla Highlights - Tesla's stock rose over 3%, reaching a nearly one-year high, with a market value increase of over $53 billion in one night [1][4]. - CEO Elon Musk's net worth surpassed $600 billion, making him the first person in history to achieve this milestone [4]. iRobot Situation - iRobot's stock plummeted over 72% after the company filed for bankruptcy protection, planning to be taken over by its main Chinese supplier and manufacturer, leading to its delisting [1][5]. Chinese Stocks Performance - The Nasdaq Golden Dragon China Index fell by 2.17%, with notable declines in stocks such as Baidu (down nearly 5%) and Alibaba (down over 3%) [1][7]. Nasdaq Trading Mechanism - Nasdaq plans to submit a proposal to the SEC to introduce a near-around-the-clock trading mechanism, extending trading hours from 16 to 23 hours per week [1][14]. - The new trading schedule would include two trading periods: a daytime session starting at 4 AM and ending at 8 PM, and a night session from 9 PM to 4 AM [14][15].

R&D Spending and Performance - R&D spending has significantly increased in the 21st century, with total R&D spending in the Nasdaq Global Large Cap™ Index tripling from $342 billion in 2008 to over $1 trillion by 2023 [1] - The top quartile of R&D spenders increased their R&D as a percentage of sales from approximately 13% in 2008 to around 18% in 2024, reinvesting six times more of their revenue into R&D compared to the bottom three quartiles [1] - Companies in the top quartile experienced revenue growth of approximately 115%, compared to 27% for others, indicating a strong correlation between R&D intensity and revenue growth [1] - An equal-weighted portfolio of top R&D spenders outperformed bottom spenders by about three times, achieving a total return of 713% versus 271% from July 2009 to December 2024 [1] - Companies in the bottom three quartiles of R&D spending showed performance nearly identical to those that spent nothing on R&D, suggesting that R&D intensity is more critical than nominal spending [1] Nasdaq International Patent Leaders Index (NQIPL) - The NQIPL consists of the top 100 companies ranked by patent valuation in the Nasdaq Global Ex United States Large Mid Cap™ Index, capturing over 80% of aggregate patent value generated outside the US [4] - The index was launched on June 24, 2024, to provide a benchmark for innovation-driven companies based outside the US, reflecting significant international R&D spending and patent filings [4] - As of June 30, 2025, the NQIPL had a price-to-earnings ratio of 17.6, which is 28% lower than the S&P 500, indicating a valuation discount for innovative companies outside the US [19] - The index's top 20 constituents represent approximately 65% of total exposure, including major companies like Taiwan Semiconductor and Tencent, with a combined market value of $5.4 trillion as of June 30, 2025 [13] Geographic and Sector Exposure - The NQIPL has a significant concentration in Japan, which accounts for nearly 25% of the index weight, with major companies like Sony and Toyota leading in patent development [11] - Technology companies make up about 36% of the index weight, followed by Industrials at 18%, and Consumer Discretionary and Healthcare at 14% each, reflecting a focus on innovation-driven sectors [12] - The index has shown a trend of increasing exposure to Taiwan, South Korea, and China, while Japan and Switzerland's exposure has generally trended lower [24] Performance Analysis - Since its launch, the NQIPL has generated a price return of 11.3% and a total return of 13.9%, with significant contributions from Technology and Industrials sectors [15] - In the first half of 2025, the NQIPL achieved a price return of 15.8%, slightly outperforming the MSCI ACWI Ex-USA [16] - Backtested performance from June 21, 2013, to June 21, 2024, indicates a total return of 202%, significantly outperforming leading international equity benchmarks [21]

Group 1 - Broadcom shares fell over 5%, while Apple and Amazon rose over 1%, and Tesla increased by over 3%, adding $53.7 billion (approximately 378.6 billion RMB) to its market value [1] - Elon Musk's net worth reached $677 billion, making him the first person in history to surpass the $600 billion mark, previously no one had crossed $500 billion [3] - iRobot officially declared bankruptcy with a stock value of zero after finalizing its restructuring plan on December 15, resulting in a 72.69% drop in its shares [3] Group 2 - The Nasdaq Golden Dragon China Index fell by 2.17%, with major Chinese stocks declining; Baidu dropped nearly 5%, and Alibaba, Xpeng Motors, and others fell over 3% [5] - WTI crude oil futures decreased by 1.08% to $56.82 per barrel, while Brent crude oil futures fell by 0.92% to $60.56 per barrel [6] - Bitcoin fell below $86,000 for the first time in two weeks, dropping 3.3% to $85,578, approximately 30% down from its record high of over $126,000 [6][7] Group 3 - Over the past 24 hours, more than 190,000 traders were liquidated, resulting in a total loss of $670 million (approximately 4.7 billion RMB) [9] - The New York Federal Reserve's manufacturing index unexpectedly shrank to -3.9 in December, indicating a contraction in economic activity, significantly below the expected median of 10 [11][13] - Federal Reserve Governor Milan suggested that the current monetary policy is too tight and advocated for a faster pace of rate cuts, citing signs of a cooling labor market [13]

Group 1 - Broadcom's stock fell over 5%, while Apple and Amazon rose over 1%, and Tesla increased by over 3%, adding $53.7 billion (approximately 378.6 billion RMB) to its market value [1] - Elon Musk is on track to become the world's first trillionaire, with a net worth of $677 billion, making him the first person in history to surpass the $600 billion mark [1] Group 2 - Cryptocurrency mining and reserve concepts saw significant declines, with Hut8 dropping over 14%, Circle down over 9%, and Coinbase falling over 6% [4] - The automotive, precious metals, tourism, and weight loss drug sectors experienced gains, with Toyota and Eli Lilly rising over 3%, and Amgen, Pfizer, and Roche increasing over 2% [4] Group 3 - iRobot's stock plummeted by 72.69% following its bankruptcy restructuring plan, resulting in its stock value reaching zero [4] - The Nasdaq Golden Dragon China Index fell by 2.17%, with major Chinese stocks like Baidu down nearly 5% and Alibaba, XPeng, and Li Auto dropping over 3% [6] Group 4 - WTI crude oil futures fell by 1.08% to $56.82 per barrel, while Brent crude oil futures decreased by 0.92% to $60.56 per barrel [7] - Bitcoin dropped 3.3% to $85,578, marking its first decline below $86,000 in two weeks, and is down approximately 30% from its record high of over $126,000 [8] Group 5 - Over 190,000 traders faced liquidation, resulting in $670 million (approximately 4.7 billion RMB) lost in the past 24 hours [10] - U.S. economic data fell significantly short of expectations, with the New York Fed manufacturing price index at 19.8, down from a previous value of 24 [11]

Market Overview - The three major U.S. stock indices closed lower, with the Dow Jones down 0.09%, the Nasdaq down 0.59%, and the S&P 500 down 0.16% [1] - Broadcom saw a decline of over 5%, while Apple and Amazon both increased by over 1%, and Tesla rose by over 3% [1] Sector Performance - Cryptocurrency mining and reserve concepts experienced significant declines, with Hut8 dropping over 14%, Circle down over 9%, and Coinbase falling over 6% [1] - The automotive manufacturing, precious metals, tourism, and weight loss drug sectors saw gains, with Toyota and Eli Lilly both rising over 3%, and Amgen, Pfizer, and Roche increasing by over 2% [1] Chinese Stocks - The Nasdaq Golden Dragon China Index fell by 2.17%, with notable declines in popular Chinese stocks such as Pony.ai and Baidu, both down 4.9%, Alibaba down 3.5%, and Xpeng down 3.5% [1] - Other Chinese companies like Li Auto and WeRide dropped over 2%, while JD.com, Xiaomi Group ADR, Pinduoduo, and Yum China all fell by over 1% [1]

Core Viewpoint - The U.S. stock market experienced a collective decline, with the Dow Jones down 0.09%, the Nasdaq down 0.59%, and the S&P 500 down 0.16% [1] Group 1: Stock Performance - Broadcom saw a significant drop of over 5% [1] - Apple and Amazon both increased by over 1%, while Tesla rose by over 3% [1] Group 2: Sector Performance - Cryptocurrency mining and reserve concepts faced notable declines, with Hut8 down over 14%, Circle down over 9%, and Coinbase down over 6% [1] - The automotive manufacturing, precious metals, tourism, and weight loss drug sectors experienced gains, with Toyota and Eli Lilly both up over 3%, and Amgen, Pfizer, and Roche all up over 2% [1]

The U.S. Food and Drug Administration has approved Daiichi Sankyo's therapy in combination with Roche's drug for the first-line treatment of patients with a type of breast cancer, the regulator said o... ...

Core Viewpoint - Zealand Pharma is seeking partners for innovative weight loss treatments that target the brain directly, emphasizing the central nervous system's role in metabolic regulation and immune response [4][6]. Group 1: Strategic Collaborations - Zealand is exploring collaborations to develop therapies that can cross the blood-brain barrier, with a focus on "shuttle technology" to safely deliver drugs to the brain [4][6]. - The company has engaged in discussions with Roche and other institutions regarding brain-targeted research, acknowledging the high difficulty of these projects but recognizing their potential to fundamentally change metabolic disease treatment [6]. - Zealand has entered a partnership with OTR Therapeutics, paying a $20 million upfront fee, potentially reaching $30 million, to leverage OTR's oral small molecule platform for new metabolic disease therapies [8]. Group 2: Product Pipeline and Development - Zealand's pipeline includes the promising drug petrelintide, which is expected to show an average weight loss of 8.6% over 16 weeks in its Phase II trial, with results anticipated in mid-2026 [9]. - The company is also advancing the dual agonist survodutide in Phase III trials for obesity and MASH, alongside other candidates targeting short bowel syndrome and congenital hyperinsulinism [9]. - Zealand's strategy includes a roadmap titled "Metabolic Frontier 2030," aiming to launch five products by 2030, indicating a long-term vision for growth in the metabolic disease sector [9]. Group 3: Market Position and Future Outlook - Zealand is aware of the competitive landscape in oral weight loss medications, particularly with Novo Nordisk's oral semaglutide awaiting regulatory approval, and is cautious about committing to outcomes without believing in their potential [8]. - The company has a robust research capability and financial reserves, allowing it to navigate uncertainties in the market while continuing to innovate [9]. - Zealand's future innovations may include improving insulin sensitivity unrelated to weight and directly modulating brain receptors, showcasing a commitment to long-term health impacts [10].